Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Pravachol OTC Label Studies, Redefined Population Urged By Cmte.

Executive Summary

Bristol-Myers Squibb's Pravachol (pravastatin) 10 mg is an attractive candidate for OTC status, but the company should first conduct additional label comprehension studies and better define the target population for the cholesterol agent, FDA advisory committee members suggested July 14.

You may also be interested in...



OTC Pravachol Use Among Rx Patients Needs More Study, FDA Cmte. Says

The reason individuals switch from taking prescription cholesterol-lowering agents to OTC Pravachol (pravastatin) in actual use studies should be the subject of additional research, FDA advisory committee members suggested to Bristol-Myers Squibb July 14.

Pravachol Rx Interaction Profile Is Viewed Favorably In Statins OTC Review

The drug interaction profile of Bristol-Myers Squibb's Pravachol may make the cholesterol-lowering agent a more attractive OTC switch candidate than Merck's Mevacor, members of the statin OTC switch advisory committee suggested.

Bristol OTC Pravachol Study Enrollment Does Not Match Indication - FDA

Bristol-Myers Squibb may need to better demonstrate consumers' ability to make self-selection choices based on appropriate cholesterol levels in order to convince FDA that an OTC version of Pravachol is approvable.

Related Content

UsernamePublicRestriction

Register

PS036335

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel